Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baloxavir vs Oseltamivir for Influenza Post-Exposure Prophylaxis
NCT06762587Not yet recruiting
- Sponsor
- Capital Medical University
- Start
- Jan 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of baloxavir marboxil in influenza (3 arms), sponsored by Capital Medical University. Primary endpoint: Incidence of Clinical Influenza within a 5-day period. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06762587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762587.